Octant Biotech

Executive Summary

Octant Biotech is a private US-based biotechnology company founded in 2018 that combines next-generation biology, chemistry, and computation to engineer precision small molecule therapeutics. The company focuses on correcting diseases of protein misfolding and mistrafficking, moving beyond traditional single-target approaches. Its lead program targets retinitis pigmentosa, a genetic cause of blindness, and is currently in Phase 1/2 clinical development. Octant's platform integrates high-throughput screening, computational modeling, and cellular biology to identify molecules that modulate complex cellular mechanisms driving disease. The company is headquartered in Emeryville, California, and has raised undisclosed funding to advance its pipeline. Octant's approach addresses a significant unmet need in protein misfolding diseases, where existing treatments are limited. Its lead candidate has the potential to be a first-in-class therapy for retinitis pigmentosa, with initial clinical data expected in the near term. The company also has preclinical programs targeting other protein misfolding disorders. As a private company, Octant's key milestones include clinical data readouts, potential partnership agreements, and future financing rounds. Its technology platform is broadly applicable, positioning it for expansion into additional indications. The company's success hinges on demonstrating clinical proof-of-concept and securing strategic collaborations to support late-stage development and commercialization.

Upcoming Catalysts (preview)

• H2 2026Phase 1/2 clinical data readout for lead retinitis pigmentosa program60% success
• H1 2027Strategic partnership or licensing deal for platform technology40% success
• H1 2027Series B or additional financing round70% success